TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04737512

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based ADHD Treatment for Children
Description: MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based ADHD Treatment for Children
Description: MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-Standard Medication (Treatment as Usual)
Description: Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-Standard Medication (Treatment as Usual)
Description: Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated.
Study: NCT05226507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXP800
Description: NXP800 is an anti-neoplastic, oral small molecule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXP800
Description: NXP800 is an anti-neoplastic, oral small molecule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXP800
Description: NXP800 is an anti-neoplastic, oral small molecule.
Study: NCT05736666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill-based perturbation training
Description: The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side. These disturbances require a compensatory step to respond. Through this task-specific training, participants should learn to control their trunk motion in a way that will cause them to avoid a trip or fall to the side.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Fall prevention educational material
Study: NCT05557916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehab
Description: Standard rehab protocol including knee orthosis following meniscal repair

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: accelerated rehab group
Description: accelerated rehab group, no orthosis
Study: NCT06473922

Intervention type: PROCEDURE
Intervention: Reginal anesthesia
Description: General anesthesia

Intervention type: PROCEDURE
Intervention: Reginal anesthesia
Description: General anesthesia
Study: NCT05776017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3-CRM-Vac4All/ Alhydrogel®
Description: 30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Rabies Vaccine
Description: Control vaccine
Study: NCT05035524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Solution
Description: Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06140602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention shake
Description: The pecan shake contains 69g of pecans
Study: NCT05478408

Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
Study: NCT04839341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Study: NCT05818488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental mind-body intervention
Description: A meditation will be guided by an audio through headphones. The audio will last 15 minutes with an initial invitation to centering (full attention to the state of the body and the breath, bringing the attention to the present moment), followed by body scanning, followed by targeting the seven dimensions of interoceptive capacity (noticing, not being distracted, not worrying, attentional regulation, emotional awareness, self-regulation, and trust), and the passive control group (waiting room)
Study: NCT06510374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
Study: NCT05476445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Root canal treatment
Study: NCT06378268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone 10 mg
Description: Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix 0.25 mg
Description: Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
Study: NCT05476445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Root canal treatment+Laser application

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Root canal treatment + Cryotherapy application
Study: NCT05769296

Intervention type: DEVICE
Intervention: Headpulse measurements
Description: Placement of headset on subject
Study: NCT05249868

Intervention type: OTHER
Intervention: Exposure SARS-CoV-2 Infection
Description: The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for \<5 days is positive on a PRAg test.
Study: NCT05330312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy
Description: Therapy for patients with pulmonary fibrosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy
Description: Therapy for patients with pulmonary fibrosis
Study: NCT04842747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
Study: NCT05362487

Intervention type: DEVICE
Intervention: Spiriva® Respimat®
Description: Spiriva® Respimat®

Intervention type: DEVICE
Intervention: Spiriva® HandiHaler®
Description: Spiriva® HandiHaler®

Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide
Study: NCT06217042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Description: Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine; capecitabine
Description: Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
Study: NCT05359458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Liberation Technique
Description: The investigators will apply Emotional Freedom Liberation Technique
Study: NCT05246046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide Monohydrate
Description: In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
Study: NCT05249140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
Study: NCT05414526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InterCARE package
Description: The InterCARE package includes:~1. Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~2. Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~3. Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other.
Study: NCT05594459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini invasive analgesic technique
Description: patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high opioids dosages
Description: patients will be treated with high opioids dosages
Study: NCT05090280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614 solution
Description: PF614 solution is an oxycodone prodrug
Study: NCT04960527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Description: 250 mL tart cherry juice (30 mL tart cherry concentrate \[CherryActive, UK\] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
Study: NCT05090280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614 solution
Description: PF614 solution is an oxycodone prodrug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
Study: NCT04960527

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
Study: NCT05090280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
Study: NCT05834881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management (CM) combined with vocational/educational coaching
Description: Two evidence based practices, CM and vocational/educational coaching, will be combined and delivered by paraprofessional coaches in an intervention named PEERS (Peers Education Empowering Recovery Supports). CM uses positive reinforcement (e.g., chances to win prizes) for clients who abstain from substance use. A standardized and well-validated CM protocol will be used in the proposed study. Vocational/educational coaching assists individuals in completing educational and vocational goals. A workbook developed specifically for vocational/educational coaching in emerging adults will be used in the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) combined with vocational/educational coaching
Description: Two evidence based practices, CM and vocational/educational coaching, will be combined and delivered by paraprofessional coaches in an intervention named PEERS (Peers Education Empowering Recovery Supports). CM uses positive reinforcement (e.g., chances to win prizes) for clients who abstain from substance use. A standardized and well-validated CM protocol will be used in the proposed study. Vocational/educational coaching assists individuals in completing educational and vocational goals. A workbook developed specifically for vocational/educational coaching in emerging adults will be used in the study.
Study: NCT06165809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3015 tablets
Description: TQB3015 is a protein inhibitor
Study: NCT06041568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imvotamab
Description: Administered intravenously
Study: NCT06222632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind diet intervention
Description: These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind plus FB intervention
Description: The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 \&amp; 12 of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
Study: NCT05088564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-sewn
Description: Doudenojejunal anastomosis by hand-sewn method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemi-double stapling
Description: Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis
Study: NCT04917146

Intervention type: OTHER
Intervention: Self-administered questionnaires for relatives (caregivers=CG)
Description: Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided.
Study: NCT05230134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical sympathetic block
Description: All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
Study: NCT05269914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous anti-CD19 CAR-T cell injection
Description: According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed.
Study: NCT05656417

Intervention type: BEHAVIORAL
Intervention: Temporary cessation of all oral hygiene
Description: Participants will refrain from all oral hygiene for 3 weeks.

Intervention type: BEHAVIORAL
Intervention: Temporary cessation of all oral hygiene
Description: Participants will refrain from all oral hygiene for 3 weeks.
Study: NCT04728958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude
Description: A positive psychology intervention using expressions of gratitude

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gratitude
Description: A positive psychology intervention using expressions of gratitude
Study: NCT04735263

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin 80mg
Description: Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
Study: NCT04820595

Intervention type: DIAGNOSTIC_TEST
Intervention: RASS
Description: Richmond Agitation-Sedation Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: RASS
Description: Richmond Agitation-Sedation Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: RASS
Description: Richmond Agitation-Sedation Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM-ICU
Description: Confusion Assessment Method for the ICU

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM-ICU
Description: Confusion Assessment Method for the ICU
Study: NCT06576661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTRARENAL PRESSURE MONITORING VISIBLE
Description: In Arm 1, participants will undergo URS with real-time IRP monitoring visible to surgeons using the LithoVue Elite™.
Study: NCT04820595

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM-ICU
Description: Confusion Assessment Method for the ICU
Study: NCT05425784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral treatment
Description: The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene self care
Description: Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene self care
Description: Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.